Semaglutide targets the GLP-1 pathway exclusively, while tirzepatide stimulates both GLP-1 and GIP receptors, a combination that clinical evidence suggests may produce stronger appetite suppression and metabolic effects
PRESENTACIN DE LOS CASOS Caso 1 Se trata de un varn de 42 aos, sin antecedentes clnicos de inters ni antecedentes familiares de melanoma que presentaba mculas irregulares heterocrmicas, de aos de evolucin en pene, que haban experimentado segn refera el paciente aumento de tamao reciente (fig
Forget broad-spectrum sunscreen active ingredients can make your skin more sensitive to the sun
SIRT1 functions as a key hub integrating metabolic, immune, and stress pathways in MASLD progression
The same starting dose applies postpartum, but the duration at each level typically extends: Weeks 1 through 8: 2.5 mg weekly Weeks 9 through 16: 5 mg weekly Weeks 17 through 24: 7.5 mg weekly Weeks 25 and beyond: 10 mg weekly (if needed) Maximum dose: 15 mg weekly Many postpartum women find that 5 mg or 7.5 mg is their effective maintenance dose and do not need to escalate to 10 or 15 mg
O GLP-1 (Glucagon-like Peptide-1) um hormnio que produzido pelo nosso intestino, liberado na presena de glicose, e que sinaliza ao crebro que estamos alimentados, diminuindo o apetite
